New combo therapy aims to rally immune system against tough lymphomas
NCT ID NCT06536049
Summary
This study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune cells find and attack the cancer, while the other aims to weaken the cancer cells directly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Minnesota/Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.